J3375 NDC Crosswalk, Billing Units, ASP Payment & Medicare Reimbursement

📋 J3375 summary

J3375 is a HCPCS Level II J-code used to bill vancomycin (xellia) 10mg, billed per 10 MG. The number of billing units to report depends on the dose administered and the NDC/package billed — use the calculator below.

Brand names associated with J3375: Tyzavan*, Tyzavan, Vancomycin

Code J3375 Billing unit 10 MG Payment limit $0.142/unit NDC-Crosswalk 15 Quarter Q3 2026 RxCUI Atlas Trace the drug concept →

⚠ An NDC↔HCPCS crosswalk and a published payment limit do not guarantee payer coverage or payment. Always verify the current payer policy and claim format before billing.

🗂️ Key billing facts

HCPCS codeJ3375

DescriptorInj vancomycin (xellia) 10mg

Billing unit10 MG

Payment limit / unit$0.142

Est. ASP / unit$0.134 est.

Mapped NDCs15

Data periodQ3 2026

Last updated2026-08-20

💊 About Vancomycin DRUG GUIDE

Vancomycin is used to fight serious bacterial infections caused by certain hard-to-treat bacteria, including methicillin-resistant Staphylococcus aureus (MRSA).

When given intravenously (by IV), it treats conditions like septicemia (a serious bloodstream infection), infective endocarditis (infection of the heart valves), skin and skin structure infections, bone infections, and lower respiratory tract infections.When taken by mouth — as capsules or oral solution (brands include Vancocin and Firvanq) — vancomycin treats Clostridioides difficile-associated diarrhea (C.

diff) and staphylococcal enterocolitis (a gut infection caused by Staphylococcus aureus).

It's important to know that the oral form does not work for bloodstream or other serious infections, and the IV form does not work for C.

Read the full Vancomycin drug guide →

Clinical overview from our editorial drug guide for Vancomycin. For billing reference, see the sections above.

🧾 Billing & reimbursement HCPCS · CMS · EFF. Q3 2026

📅 Payment limits effective Q3 2026 — from the CMS Medicare Part B Payment Limit File (revised quarterly).

Medicare payment limit / unit

$0.142

Est. ASP / unit

$0.134 est.

Est. after 2% sequester

$0.139

HCPCS dosage

10 MG

The CMS payment limit is the Medicare Part B drug allowance (ASP + 6%, statutory). After the 2% federal sequester the effective payment is ≈ ASP + 4.3%; estimated ASP = payment limit ÷ 1.06. Source: CMS Medicare Part B Payment Limit File (quarterly), Q3 2026.

🧮 Dosing & billing-units calculator HCPCS UNITS

One billing unit of J3375 = 10 mg. Enter a regimen to convert dose → billing units and project a full course.

Dose per administration (mg) Frequency — every days Number of doses NDC / package billed (optional)

Billing units = dose ÷ HCPCS unit size. Most payers require whole units — round per the payer's policy. “Est. Medicare pay” uses the current payment limit. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (JZ when none is discarded) where allowed. Always verify payer-specific rounding before billing.

🔁 NDCs that bill under J3375 WITH EST. MEDICARE PAY

15 NDCs map to J3375. Bill units = how many HCPCS units one package represents. Est. pay / pkg = payment limit ($0.142/unit) × that package's bill units.

NDC (11-digit)	Drug	Labeler	Package	Strength	Bill units	Est. pay / pkg	NADAC / unit	Status	Source
00143-9466-06	TYZAVAN Vancomycin 1.25 g/250mL INJECTION, SOLUTION	Hikma	6 BAG in 1 CARTON (0143-9466-06) / 250 mL...	1.25 g/250mL	750	$106.50	—	● Active	CMS + PDAC
00143-9467-06	TYZAVAN Vancomycin 1.75 g/350mL INJECTION, SOLUTION	Hikma	6 BAG in 1 CARTON (0143-9467-06) / 350 mL...	1.75 g/350mL	1,050	$149.10	—	● Active	CMS + PDAC
00143-9468-12	TYZAVAN Vancomycin 750 mg/150mL INJECTION, SOLUTION	Hikma	12 BAG in 1 CARTON (0143-9468-12) / 150 m...	750 mg/150mL	900	$127.80	—	● Active	CMS + PDAC
00143-9469-06	TYZAVAN Vancomycin 1.5 g/300mL INJECTION, SOLUTION	Hikma	6 BAG in 1 CARTON (0143-9469-06) / 300 mL...	1.5 g/300mL	900	$127.80	—	● Active	CMS ASP
00143-9470-06	TYZAVAN Vancomycin 2 g/400mL INJECTION, SOLUTION	Hikma	6 BAG in 1 CARTON (0143-9470-06) / 400 mL...	2 g/400mL	1,200	$170.40	—	● Active	CMS ASP
00143-9471-12	TYZAVAN Vancomycin 500 mg/100mL INJECTION, SOLUTION	Hikma	12 BAG in 1 CARTON (0143-9471-12) / 100 m...	500 mg/100mL	600	$85.20	—	● Active	CMS ASP
00143-9472-12	TYZAVAN Vancomycin 1 g/200mL INJECTION, SOLUTION	Hikma	12 BAG in 1 CARTON (0143-9472-12) / 200 m...	1 g/200mL	1,200	$170.40	—	● Active	CMS ASP
70594-0041-03	Vancomycin 500 mg/100mL INJECTION, SOLUTION	Xellia	12 BAG in 1 CARTON (70594-041-03) / 100 m...	500 mg/100mL	600	$85.20	—	● Active	CMS ASP
70594-0042-03	Vancomycin 1 g/200mL INJECTION, SOLUTION	Xellia	12 BAG in 1 CARTON (70594-042-03) / 200 m...	1 g/200mL	1,200	$170.40	—	● Active	CMS ASP
70594-0043-02	Vancomycin 1.5 g/300mL INJECTION, SOLUTION	Xellia	6 BAG in 1 CARTON (70594-043-02) / 300 mL...	1.5 g/300mL	900	$127.80	—	● Active	CMS ASP
70594-0044-02	Vancomycin 2 g/400mL INJECTION, SOLUTION	Xellia	6 BAG in 1 CARTON (70594-044-02) / 400 mL...	2 g/400mL	1,200	$170.40	—	● Active	CMS ASP
70594-0056-03	Vancomycin 750 mg/150mL INJECTION, SOLUTION	Xellia	12 BAG in 1 CARTON (70594-056-03) / 150 m...	750 mg/150mL	900	$127.80	—	● Active	CMS + PDAC
70594-0057-02	Vancomycin 1.25 g/250mL INJECTION, SOLUTION	Xellia	6 BAG in 1 CARTON (70594-057-02) / 250 mL...	1.25 g/250mL	750	$106.50	—	● Active	CMS + PDAC
70594-0058-02	Vancomycin 1.75 g/350mL INJECTION, SOLUTION	Xellia	6 BAG in 1 CARTON (70594-058-02) / 350 mL...	1.75 g/350mL	1,050	$149.10	—	● Active	CMS + PDAC
00143-9468-06	TYZAVAN Vancomycin 750 mg/150mL INJECTION, SOLUTION	Hikma	6 BAG in 1 CARTON (0143-9468-06) / 150 mL...	750 mg/150mL	0.5	$0.07	—	● Active	PDAC

NDC→HCPCS mappings come from the CMS ASP NDC-HCPCS crosswalk; additional DME MAC / DMEPOS mappings come from PDAC and are labeled separately. NADAC from CMS (weekly). “Status” reflects the product's marketing / obsolete flag in the NDC directory. Presence or absence here does not determine Medicare coverage. Linked NDCs open the full product page.

⚠️ Don't confuse J3375 with… RELATED CODES

Adjacent HCPCS codes that share an ingredient or formulation with J3375. Billing units and payment limits differ — confirm the exact code, strength and form before billing.

Code	Descriptor	Billing unit	Payment limit / unit	How it differs from J3375
J3370	Vancomycin hcl injection	—	—	Related ingredient or formulation — confirm strength, form and billing unit before substituting.
J3373	VANCOMYCIN*	10 MG	$0.033	Related ingredient or formulation — confirm strength, form and billing unit before substituting.
J3374	VANCOMYCIN HCL	10 MG	$0.097	Related ingredient or formulation — confirm strength, form and billing unit before substituting.
J3371	Inj, vancomycin hcl (mylan)	—	—	Related ingredient or formulation — confirm strength, form and billing unit before substituting.
J3372	Inj, vancomycin hcl (xellia)	—	—	Related ingredient or formulation — confirm strength, form and billing unit before substituting.

Related codes matched on shared ingredient (CMS Medicare Part B Spending feed). Billing units and payment limits from the CMS ASP Pricing File. Always verify the precise HCPCS code for the product and strength administered.

📊 Medicare utilization & spend CMS · PART B · 2026 (Q1)

Period

Total Part B spend

$1.1K

Claims

35

Beneficiaries

12

Spend / beneficiary

$92.47

Spend / claim

$31.70

Trend by period

Where J3375 ranks among Part B drugs · 2026 (Q1) · neighbors ±5

Total spending — #767 of 824

#762 BUMETANIDE J1939 $1.2K #763 CEFOXITIN SODIUM* J0694 $1.2K #764 GASTROGRAFIN* Q9963 $1.1K #765 VANCOMYCIN HCL(J3374... J3374 $1.1K #766 METHOCARBAMOL* J2800 $1.1K #767 TYZAVAN* J3375 $1.1K #768 PENICILLIN G POTASSI... J2540 $1.1K #769 STREPTOMYCIN SULFATE J3000 $1.1K #770 AMPHOTERICIN B J0285 $1.1K #771 HAVRIX* 90632 $1K #772 TIGECYCLINE* J3243 $940.10

Total claims — #727 of 824

#722 FLUCONAZOLE-NACL J1450 38 #723 VANCOMYCIN HCL(J3374... J3374 38 #724 PERSERIS J2798 37 #725 XYNTHA SOLOFUSE* J7185 37 #726 PEMETREXED(J9314) J9314 37 #727 TYZAVAN* J3375 35 #728 HEPZATO J9248 35 #729 HYCAMTIN J8705 34 #730 LAMZEDE J0217 33 #731 ZEMDRI J0291 33 #732 DOXY 100* J1271 33

Full breakdown by period (2)

Period	Total spend	Beneficiaries	Claims	$/beneficiary	$/claim
2026 (Q1)	$1.1K	12	35	$92.47	$31.70
2025 (Q1-Q4)	$5.1K	29	90	$176.39	$56.84

Provider-administered (Part B) spend, calculated for the whole HCPCS code (CMS does not publish Medicare spend per individual NDC). Self-administered use is covered under Part D instead. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part B Spending by Drug (data.cms.gov), updated quarterly.

📈 Medicare Part B claims detail CMS PSPS · 2024

Calendar-year 2024 Medicare Part B fee-for-service activity for this HCPCS code, summed across all carriers, localities and specialties (CMS Physician/Supplier Procedure Summary). A “service” is one billed line/unit — not one claim — so counts run higher than claim counts.

Allowed charges

$146.74

Medicare paid

$116.09

Submitted services

7,060

Denial rate

85.0%

Allowed / service

$0.14

Submitted charges

$2.2K

Source: CMS Physician/Supplier Procedure Summary (PSPS), CY2024 — Medicare Part B carrier + DME fee-for-service claims (excludes Medicare Advantage). Figures are for the whole HCPCS code, which may cover uses beyond this drug. ⚠ CMS hides any figure covering fewer than 11 patients (a privacy rule), so totals — especially denials and low-volume codes — run a little low.

🗺️ Where J3375 is utilized

⏳

The geographic utilization map is building for this code — it aggregates millions of CMS Part B claim lines, then caches the result. Refresh in a moment; if it doesn’t appear, this code may have no reportable Part B utilization.

📊 What bills under J3375

J-codes are billing codes often used for drugs billed under the medical benefit. This connects the billing code to the NDC package records it covers, by ingredient and labeler.

NDC products by ingredient

Vancomycin 12

NDC products by labeler

Hikma Pharmaceuticals USA Inc. 9

Xellia Pharmaceuticals USA LLC 3

🔗 Related NDC directory pages

🧪 All Vancomycin NDCsIngredient 🏭 All Hikma labeler NDCsLabeler 00143 🏭 All Xellia labeler NDCsLabeler 70594 📚 All Glycopeptide Antibacterial NDCsDrug class

🗃️ Data sources & freshness

Every figure on this page is computed from public datasets. Here's what each section draws on and how current it is.

HCPCS code & descriptor

CMS HCPCS Level II code file

Not available in current dataset

Payment limit & billing unit

CMS Medicare Part B ASP Pricing File (quarterly)

Q3 2026 · as of 2026-08-20

NDC ↔ HCPCS crosswalk

CMS ASP NDC-HCPCS crosswalk + DMEPDAC (PDAC)

15 NDCs mapped

NADAC acquisition cost

CMS National Average Drug Acquisition Cost (weekly)

Not available for mapped NDCs

Utilization & spend

CMS Part B Spending by Drug · PSPS · Physician & Other Practitioners

Latest data year 2026

Figures are estimates for reference and may lag the source files. Always verify against the current CMS files and your payer's policy before submitting claims.

⚠️ Practical billing caveats

A crosswalk is not coverage. An NDC mapping or a published payment limit does not guarantee a payer will cover or pay this code. Check the specific plan's policy.
Units ≠ milligrams. Bill the number of HCPCS units (dose ÷ the code's unit size), not the milligram dose. Use the calculator above.
Discarded drug. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (and JZ when nothing is discarded) where the payer allows.
Rounding & partial units. Many payers require whole units; round per the payer's policy, not automatically up.
The code can cover more than this drug. Some HCPCS codes span multiple products or strengths — confirm the exact code for the product administered.
Figures lag. ASP limits change quarterly and utilization data are released with a delay. Verify against the current CMS files before billing.

❓ J3375 billing FAQ

What is HCPCS code J3375?

J3375 is a HCPCS Level II J-code used to bill Inj vancomycin (xellia) 10mg under Medicare Part B and most medical (not pharmacy) benefits.

What is the billing unit for J3375?

One unit of J3375 represents 10 MG. Report the number of units equal to the dose administered divided by 10 MG.

How many units of J3375 should I bill?

Divide the dose administered by the code's unit size (10 MG) to get the number of billing units, then round per your payer's policy. The calculator on this page converts a dose into billing units and projects a full course.

How much does Medicare pay for J3375?

The Medicare Part B payment limit is $0.142 per unit (Q3 2026), based on ASP + 6%. After the 2% sequester the effective payment is about $0.139 per unit. Payment limits are revised quarterly.

Which NDCs bill under J3375?

15 NDCs currently map to J3375 in the CMS ASP NDC-HCPCS crosswalk. See the NDC crosswalk table above for each product, package, billing units and estimated reimbursement.

Does a crosswalk mean J3375 is covered?

No. An NDC-to-HCPCS crosswalk and a published payment limit do not guarantee coverage or payment. Coverage depends on the payer, the diagnosis and the site of care — always verify the current policy before billing.

J3375 – Inj vancomycin (xellia) 10mg · NDC Crosswalk & Billing Units